Message Font: Serif | Sans-Serif
No. of Recommendations: 2

I'm a KG stock holder and though I like the company, they've got issues which hasn't been satisfactorily addressed for the past couple of quarters.

Number (1) concern is the increasing levels of inventories, which is far outpacing sales by at least a factor of 2. I'm not surprised it's affecting their two largest gross margin revenue earners Altace and Levoxyl. I don't believe management hasn't adequately address this in the 3Q 2003 conference call.

Number (2) is the slowing in growth of the top line. King needs another blockbuster drug like Altace to excite investors. They're spending big on the R&D and the results (if any) wont be seen for a years. In the meantime, KG has a whole bunch of branded products doing less than $20 million in annual sales. What's better - 5 products that sell of $100 million or one? From a sales prespective, I'd hazard to say one.

Number (3) is the Benevolent Fund run by the executive management of KG. I don't know what others think but I'm a little uneasy on a public company donating its products to a private charity organisation run by the executive management of KG - without approval from the shareholders.

Those are my current thoughts for the moment and I'll await results from the 10Q before commenting any further.

Best of luck to all.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.